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Objective: To determine the clinical signiﬁcance of serum follistatin levels in women with an ovarian
endometrioma.
Materials and methods: This is a prospective study of 89 women, 56 with an ovarian endometrioma
(endometrioma group) and 33 with a benign ovarian cyst (control group) who underwent laparoscopic
excision. Age, parity, body mass index, serum CA-125, serum CA 19-9, and serum follistatin levels were
determined for all participants and evaluated as potential prognostic factors prior to laparoscopic
cystectomy.
Results: There were no signiﬁcant differences in demographic factors between the endometrioma group
and the control group. However, serum follistatin levels were signiﬁcantly higher in the endometrioma
group (9350± 895 pg/mL vs. control group 725± 72 pg/mL, p< 0.05). The optimal diagnostic cut-off values
(sensitivity and speciﬁcity) of CA-125, CA 19-9, and follistatin for ovarian endometrioma were 23.2 IU/mL
(82.14% and 72.73%), 30.14 IU/mL (45.28% and 87.50%), and 2350 pg/mL (53.7% and 60.61%), respectively.
Conclusion: Despite the increased serum follistatin levels in patients with ovarian endometrioma, CA-
125 was determined to be a more sensitive and speciﬁc marker than follistatin for the diagnosis of
ovarian endometrioma and endometriosis.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Endometriosis is a chronic condition characterized by the
growth of hormone-responsive endometrial tissue outside the
uterine cavity [1]. An ovarian endometrioma is a cyst composed of
endometrial tissue detected in 20e40% of women with endome-
triosis [1,2]. The gold standard for diagnosis of endometriosis is
histological examination, which requires an invasive procedure,
such as laparoscopy or laparotomy, to obtain tissue samples [3,4].
Many serum biochemical markers, such as cytokines, hormones,
and growth factors, which may be released into the bloodstream by
ectopic endometrial tissue, have been suggested for noninvasive
diagnosis of endometriosis. Although these markers have some
clinical value, diagnostic serummarkers for endometriosis have notmen's Health Education and
ahallesi 1549, Cadde, Hardem
çu).
bstetrics & Gynecology. Publishedbeen identiﬁed. CA-125, a transmembrane glycoprotein, is elevated
in women with endometriosis [5], and previous studies have re-
ported that ectopic endometrial tissue may release follistatin into
the bloodstream [5e8].
Follistatin is an extracellular glycoprotein originally identiﬁed as
an inhibitor of pituitary follicle-stimulating hormone secretion. The
majority of follistatin's physiological effects are due to its ability to
neutralize activin [9,10]. Florio et al [11] reported that follistatin is
expressed in human endometrium and ectopic endometrial tissue,
and is a promising diagnostic marker due to its sensitivity and
speciﬁcity for ovarian endometriomas.
This study compares the serum levels of follistatin in women
with ovarian endometriomas with those with benign ovarian cysts
to determine the role of follistatin in the diagnosis of ovarian
endometrioma and endometriosis.
Materials and methods
This prospective case control study was conducted between
February 2012 and May 2013 at Zekai Tahir Burak Women's Healthby Elsevier Taiwan LLC. All rights reserved.
Table 1
The demographic and clinical characteristics of the patients.
Endometrioma
group (n ¼ 56)
Benign cyst
group (n ¼ 33)
p
Age (y)a 31.71 ± 7.79 29.06 ± 10.75 0.692
Parityb 0.70 (0e3) 1.06 (0e4) 0.788
BMI (kg/cm2)a 2.77 ± 3.71 2.3 ± 3.53 0.532
Smokersc 18 (32.14) 12 (36.36) 0.365
Alcohol usec 2 (3.5) 1 (3.03) 0.278
Bilateralityc 15 (28.57) 9 (27.27) 0.976
Diameter of the mass (cm)a 5.64 ± 2.01 6.79 ± 1.56 0.007
NLRa 2.36 ± 2.21 2.39 ± 1.86 0.964
CA-125 (IU/mL)a 93.45 ± 89.55 47.25 ± 72.05 0.014
CA19-9 (IU/mL)a 84.79 ± 93.37 34.89 ± 76.9 0.010
Follistatin (pg/mL)a 9350 ± 895 725 ± 72 0.011
BMI ¼ body mass index; NLR ¼ neutrophil lymphocyte ratio.
A p value <0.05 was considered statistically signiﬁcant.
a Data are presented as mean ± SD.
b Data are presented as median (minemax).
c Data are presented as n (%).
Fig. 1. ROC curve of CA-125, CA 19-9, and follistatin for the discrimination of endo-
metrioma cases from benign cysts. AUC ¼ area under the curve; ROC ¼ receiver
operating characteristic.
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performed according to the standards of the Helsinki declaration,
and written informed consent was obtained from all participants.
The study was approved by our Institutional Ethics Committee
(ethical approval no: 22-02-12/20).
Patient characteristics
Eighty-nine women with ovarian masses were enrolled in the
study: 56 women with an ovarian endometrioma (endometrioma
group) and 33 women with a benign ovarian cyst (control group).
Age, parity, body mass index, tobacco use, alcohol use, diameter of
the ovarian mass, bilaterality of the mass, platelet count, neutrophil
leukocyte ratio, serum follistatin, serum CA-125, and serum CA 19-
9 levels were determined for each participant.
All patients in the endometrioma group had Stage 3 or 4
endometriosis according to the revised American Society for
Reproductive Medicine classiﬁcation [12]. Patients in the control
group did not have endometriosis but had benign ovarian tumors
with histological conﬁrmed ﬁnal diagnoses, including serous
(n ¼ 18) and mucinous (n ¼ 15) cystadenomas.
Blood samples
Peripheral venous blood samples were collected from all pa-
tients prior to laparoscopic cystectomy to measure serum folli-
statin, CA-125, and CA 19-9 levels. All blood samples were allowed
to clot at room temperature. Samples were centrifuged at 300g for
20 minutes at room temperature, and the serum was separated
using a disposable pipette, transferred to a cryoresistant tube, and
stored at 80C for 3e15 months (average 9 months).
Laboratory assays
The serum follistatin concentration was measured using a
commercially available enzyme-linked immunosorbent assay
(ELISA; Eastbiopharm Co., Ltd., Hangzhou, China). For the follistatin
ELISA, the intra- and inter-assay coefﬁcients of variation were 3%
and 9%, respectively.
The serum concentration of CA-125 was measured using an
electrochemiluminescence immunoassay kit (Roche Elecsys Kits,
Roche Diagnostics, Mannheim, Germany). The intra- and inter-
assay coefﬁcients of variation were 3.8% and 1.5%, respectively.
The reference range for serum CA-125 was 0e35 IU/mL.
Serum CA 19-9 was measured using an electro-
chemiluminescence immunoassay (Roche Diagnostics E 170
analyzer). A normal CA 19-9 value was deﬁned as < 27 IU/mL.
Statistical analysis
The means and standard deviations were calculated for
continuous variables, and normal distribution was analyzed using
the KolmogoroveSmirnov test. The Chi-square (c2) test and Stu-
dent t test were used to evaluate associations between the cat-
egorical and continuous variables. For non-normally distributed
categorical variables, the ManneWhitney U test was used.
Receiver operator characteristic (ROC) curve analysis was used to
establish the cut-off values for follistatin, CA-125, and CA 19-9.
The Youden index (sensitivity þ speciﬁcity  1) was also calcu-
lated, and the cut-off value with the maximum Youden index was
deemed the optimal cut-off value. A p value < 0.05 was consid-
ered statistically signiﬁcant. Statistical analyses were conducted
using SPSS 17.0 software for Windows (SPSS Inc., Chicago, IL,
USA).Results
Patient demographic and clinical features are presented in
Table 1. The mean age, parity, body mass index, tobacco use, and
alcohol use were similar between the endometrioma and the
control groups. There were no statistically signiﬁcant differences
between the groups in terms of the mean platelet count or NLR
(p > 0.05). Themean diameter of the cystic mass was 6.79 ± 1.56 cm
in the control group (benign ovarian cyst) and 5.64 ± 2.01 cm in the
endometrioma group (p < 0.05). Serum CA-125, CA 19-9, and fol-
listatin levels in the endometrioma group versus the control group
were 93.45 ± 89.55 IU/mL versus 47.25 ± 72.05 IU/mL,
84.79 ± 93.37 IU/mL versus 34.89 ± 76.9 IU/mL, and 9350 ± 895 pg/
mL versus 725 ± 72 pg/mL, respectively.
According to ROC curve analysis, the cut-off values (sensitivity
and speciﬁcity) for serum CA-125, CA 19-9, and follistatin were
23.2 IU/mL (81.14% and 72.73%), 30.14 IU/mL (45.28% and 87.5%),
and 23.5 ng/mL (53.57% and 60.61%), respectively (Fig. 1). The area
under the curve values for CA-125, CA 19-9, and follistatin were
0.814, 0.613, and 0.54, respectively (Table 2). Combining CA-125, CA
19-9, and follistatin levels using the cut-off values in Table 2
signiﬁcantly improved the diagnostic accuracy with a speciﬁcity
of 93.75% and a sensitivity of 26.8%.
Table 2
The cut-off values of tumor markers and follistatin levels in the detection of ovarian endometrioma.
Cut-off Sensitivity 95% CI Speciﬁcity 95 % CI þLR LR
CA-125 (IU/mL) 23.2 82.14 69.6e91.1 72.73 54.5e86.7 3.01 0.25
CA19-9 (IU/mL) 30.14 45.28 31.6e59.5 87.5 71e96.4 3.62 0.63
Follistatin (pg/mL) 2350 53.57 3970e6700 60.61 4210e7710 136 0.77
CI ¼ conﬁdence interval; LR ¼ likelihood ratio.
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In the present study, serum follistatin levels were measured in
women with ovarian endometriomas or benign ovarian cysts.
Serum CA-125, CA 19-9, and follistatin levels were signiﬁcantly
different between the two groups. Although the cystic mass
diameter was signiﬁcantly greater in the benign cyst control group,
serum CA-125, CA 19-9, and follistatin levels were higher in the
endometrioma group. ROC curve analysis indicated that CA-125, CA
19-9, and follistatin might be discriminative markers for ovarian
endometrioma. The sensitivity and speciﬁcity of serum follistatin
for the diagnosis of endometrioma were 53.57% and 60.61%,
respectively.
The diagnosis of endometriosis is currently dependent upon
postoperative histopathological examination, since a noninvasive
method for the diagnosis of endometriosis has yet to be validated.
Biomarkers such as CA-125, annexin V, vascular endothelial growth
factor, soluble intercellular adhesion molecule-1, and glycodelin
have been investigated as potential diagnostic markers for endo-
metriosis [13]. However, despite advanced technological de-
velopments, an ideal diagnostic biomarker has not been identiﬁed.
In a meta-analysis, CA-125 was a better diagnostic marker for
Grades 3 and 4 endometriosis than Grades 1 and 2 endometriosis
[14]. In another study, serum CA-125 levels were similar between
women with Grades 1 or 2 endometriosis and those without
endometriosis. However, serum CA-125 levels were found to be
signiﬁcantly higher in women with Grades 3 or 4 endometriosis
than Grade 1 endometriosis [15]. In the present study, all patients
in the endometrioma group had Grades 3 or 4 (severe) endome-
triosis, and when CA-125 levels were compared between the
endometrioma group and the control group, the predictive value of
CA-125 was signiﬁcantly higher in the endometrioma group with
severe endometriosis.
The diagnostic signiﬁcance of CA 19-9 levels in endometriosis
remains unclear due to conﬂicting data [16e18]. While one study
reported signiﬁcantly higher CA 19-9 levels in all stages of endo-
metriosis [16], others reported no association between serum CA
19-9 levels and endometriosis [17,18]. In the present study serum
Ca-19-9 levels were not signiﬁcantly different between the endo-
metrioma and control groups.
Follistatin was ﬁrst isolated from follicular ﬂuid [10], and 15
years after its initial isolation, it was detected in human endome-
trium [19]. Follistatinwas ﬁrst investigated as a potential biomarker
for endometriosis in 2009 by Florio et al [11].
During the late secretory phase of the menstrual cycle, Rocha
et al [20] found an increase in follistatin mRNA in the eutopic
endometrium and in endometriomas of women with endometri-
osis compared with healthy controls. Therefore, it has been sug-
gested that activin and follistatin mRNA expression are altered in
endometriosis and can be used for diagnostic purposes [20]. In
another study, follistatin, follistatin-related gene, and activin A
binding proteins showed an impaired expression pattern inwomen
with endometriosis, whichmay cause insufﬁcient angiogenesis and
endometrial differentiation due to altered activin A expression [7].
Altered follistatin expression and the subsequent physiologic
changes detailed above may account for the association betweenhigh follistatin levels and infertility in women with endometriosis.
Additional research is needed to investigate this hypothesis.
In a study by Floria et al [11], serum follistatin levels were higher
in women with ovarian endometrioma than those with benign
ovarian cysts. In addition, the level of follistatin was signiﬁcantly
higher in cystic ﬂuid than in peritoneal ﬂuid. Therefore, the authors
claim follistatin had high sensitivity and speciﬁcity for ovarian
endometrioma and was a useful diagnostic marker. However, this
ﬁnding is not consistent with data from the present study. Our data
indicate that while serum follistatin was signiﬁcantly different
between the endometrioma and control groups, CA-125 is a su-
perior diagnostic marker for the discrimination between ovarian
endometriomas and benign ovarian cysts. In a recent study of 28
biomarkers, the combined evaluation of serum annexin V, vascular
endothelial growth factor, CA-125, and soluble intercellular adhe-
sion molecule-1 or glycodelin had a sensitivity of 81e90% and a
speciﬁcity of 63e81% for the diagnosis of endometriosis [13]. In the
present study, the combination of CA-125, CA 19-9, and follistatin
levels produced a high speciﬁcity of 93.75% and a low sensitivity of
26.8% for the diagnosis of endometriosis.
In summary, follistatin may be a promising marker for the
diagnosis of endometriosis, althoughCA-125was determined to be a
superior diagnosticmarker for severe (Stages 3 and4) endometriosis
and ovarian endometrioma. There are limited studies on the asso-
ciation between follistatin levels and endometriosis in literature,
and this study provides important information about serum folli-
statin levels and endometriosis. However, additional investigations
using large study populations should be carried out to identify other
promising biomarkers for the diagnosis of endometriosis.
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